PharmaPoint: Dry Eye Syndrome - Current and Future Players

News provided by

Sep 12, 2013, 08:12 ET

NEW YORK, Sept. 12, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Dry Eye Syndrome - Current and Future Players

http://www.reportlinker.com/p01622971/PharmaPoint-Dry-Eye-Syndrome---Current-and-Future-Players.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Dry Eye Syndrome - Current and Future Players

Summary

Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation.

Scope

- Investigation of current and future market competition for DES- Competitor assessment- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.- Strategic assessment of DES sector through market impact analysis, future market scenario and company analysis.

Reasons to buy

- Gain a high level view of the trends shaping and driving DES Market- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.- Create an effective counter-strategy to gain a competitive advantage against those currently in the market- What's the next big thing in the global DES market landscape? Identify, understand and capitalize.1 Table of Contents1 Table of Contents 41.1 List of Tables 51.2 List of Figures 62 Introduction 72.1 Catalyst 72.2 Related Reports 83 Market Outlook 93.1 Global Markets 93.1.1 Forecast 93.1.2 Drivers and Barriers – Global Issues 114 Current and Future Players 144.1 Overview 144.2 Trends in Corporate Strategy 164.3 Company Profiles 174.3.1 Allergan 174.3.2 Alcon (a wholly-owned subsidiary of Novartis AG) 194.3.3 Santen Pharmaceutical 224.3.4 Shire/SARcode Bioscience 254.3.5 Otsuka Holdings 274.3.6 Can-Fite Biopharma 294.3.7 Eyegate Pharma 305 Appendix 325.1 Bibliography 325.2 Abbreviations 335.3 Methodology 345.4 Forecasting Methodology 345.4.1 Diagnosed DES patients 345.4.2 Percent Drug-treated Patients 355.4.3 Drugs Included in Each Therapeutic Class 355.4.4 Launch and Patent Expiry Dates 355.4.5 General Pricing Assumptions 365.4.6 Individual Drug Assumptions 375.4.7 Generic Erosion 415.5 Physicians and Specialists Included in this Study 425.6 About the Authors 435.6.1 Author 435.6.2 Global Head of Healthcare 445.7 About GlobalData 455.8 Contact Us 455.9 Disclaimer 45

1.1 List of Tables

Table 2: Dry Eye Syndrome Global Market – Drivers and Barriers, 2012–2022 11

Table 3: Key Companies in the Dry Eye Syndrome Market, 2012 15

Table 4: Allergan's Dry Eye Syndrome Portfolio Assessment, 2012 18

Table 5: Allergan SWOT Analysis, 2012 19

Table 6: Alcon's Dry Eye Syndrome Portfolio Assessment, 2012 20

Table 7: Alcon's Dry Eye Syndrome Portfolio SWOT Assessment, 2012 21

Table 8: Santen Pharmaceutical's Dry Eye Syndrome Portfolio Assessment, 2012 22

Table 9: Santen Pharmaceutical's Dry Eye Syndrome Portfolio Assessment, 2012 24

Table 10: Santen Pharmaceutical's Dry Eye Syndrome Portfolio SWOT Analysis, 2012 25

Table 11: Shire's Dry Eye Syndrome Portfolio Assessment, 2013 26

Table 12: Shire's Dry Eye Syndrome Portfolio SWOT Analysis, 2013 26

Table 13: Otsuka Pharmaceutical's Dry Eye Syndrome Portfolio Assessment, 2012 28

Table 14: Otsuka Pharmaceutical's Dry Eye Syndrome Portfolio SWOT Analysis, 2012 28

Table 15: Can-Fite Dry Eye Syndrome Portfolio Assessment, 2012 29

Table 16: Can-Fite's Dry Eye Syndome Portfolio SWOT Analysis, 2012 30

Table 17: Eyegate Pharma's Dry Eye Syndrome Portfolio Assessment, 2012 31

Table 18: Eyegate Pharma's Dry Eye Syndrome Portfolio SWOT Analysis, 2012 31

Table 19: Key Launch Dates 35

Table 20: Key Patent Expiries 35

1.2 List of Figures

Figure 1: Global Sales for Dry Eye Syndrome by Region, 2012–2022 11Figure 2: Company Portfolio Gap Analysis in Dry Eye Syndrome, 2012–2022 16

Companies Mentioned

Allergan Alcon (a wholly-owned subsidiary of Novartis AG)Santen Pharmaceutical Shire/SARcode Bioscience Otsuka Holdings Can-Fite Biopharma Eyegate Pharma

To order this report: PharmaPoint: Dry Eye Syndrome - Current and Future Players http://www.reportlinker.com/p01622971/PharmaPoint-Dry-Eye-Syndrome---Current-and-Future-Players.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker